Secreted osteopontin is highly polymerized in human airways and fragmented in asthmatic airway secretions. by Arjomandi, Mehrdad et al.
UCSF
UC San Francisco Previously Published Works
Title
Secreted osteopontin is highly polymerized in human airways and fragmented in asthmatic 
airway secretions.
Permalink
https://escholarship.org/uc/item/2dd0r667
Journal
PloS one, 6(10)
ISSN
1932-6203
Authors
Arjomandi, Mehrdad
Frelinger, Jessica
Donde, Aneesh
et al.
Publication Date
2011
DOI
10.1371/journal.pone.0025678
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Secreted Osteopontin Is Highly Polymerized in Human
Airways and Fragmented in Asthmatic Airway Secretions
Mehrdad Arjomandi1,2,4*, Jessica Frelinger1,2,4, Aneesh Donde2, Hofer Wong2, Amritha Yellamilli2,
Wilfred Raymond3,4
1Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America,
2Human Exposure Laboratory, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America, 3Cardiovascular
Research Institute, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America, 4 Pulmonary Research Group, San
Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America
Abstract
Background: Osteopontin (OPN) is a member of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family
and a cytokine with diverse biologic roles. OPN undergoes extensive post-translational modifications, including
polymerization and proteolytic fragmentation, which alters its biologic activity. Recent studies suggest that OPN may
contribute to the pathogenesis of asthma.
Methodology: To determine whether secreted OPN (sOPN) is polymerized in human airways and whether it is qualitatively
different in asthma, we used immunoblotting to examine sOPN in bronchoalveolar lavage (BAL) fluid samples from 12
healthy and 21 asthmatic subjects (and in sputum samples from 27 healthy and 21 asthmatic subjects). All asthmatic
subjects had mild to moderate asthma and abstained from corticosteroids during the study. Furthermore, we examined the
relationship between airway sOPN and cellular inflammation.
Principal Findings: We found that sOPN in BAL fluid and sputum exists in polymeric, monomeric, and cleaved forms, with
most of it in polymeric form. Compared to healthy subjects, asthmatic subjects had proportionately less polymeric sOPN
and more monomeric and cleaved sOPN. Polymeric sOPN in BAL fluid was associated with increased alveolar macrophage
counts in airways in all subjects.
Conclusions: These results suggest that sOPN in human airways (1) undergoes extensive post-translational modification by
polymerization and proteolytic fragmentation, (2) is more fragmented and less polymerized in subjects with mild to
moderate asthma, and (3) may contribute to recruitment or survival of alveolar macrophages.
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Introduction
Osteopontin (OPN) is a small integrin-binding ligand N-linked
glycoprotein (SIBLING) and a cytokine with diverse roles in tissue
remodeling, fibrosis, immunomodulation, inflammation, and tumor
metastasis [1,2,3,4,5,6,7]. It is synthesized at the highest levels in
bone and epithelial tissues [8,9], but is also made by activated T
lymphocytes [10,11], smooth muscle cells [12], and cells associated
with the reticuloendothelial system, including macrophages and
dendritic cells [13,14,15]. While initially thought to be exclusively a
secreted protein (sOPN), later evidence showed that OPN also
possesses intracellular forms (iOPN) [16,17].
Osteopontin undergoes major post-translational modification,
including phosphorylation at up to 36 sites and N- and O-linked
glycosylation, with subsequent increase in molecular weight of
nascent protein from 34 kD to 44–65 kD post-modification [8,18]. It
contains an Arg-Gly-Asp (RGD) motif that mediates cell attachment
and signaling via its reaction with cell-surface integrins [19].
Osteopontin is also a target of proteolytic cleavage by proteases
such as thrombin, plasmin, and cathepsin D, which exposes a cryptic
sequence (SVVYGLR) that binds to several integrin receptors
through which it mediates recruitment of inflammatory cells
including neutrophils and macrophages [20,21,22,23,24,25,26].
Furthermore, OPN is a substrate for tissue transglutaminase
(TGM2) and can undergo polymerization (as well as cross-linkage
to fibronectin) via transglutamination at Glu50-Lys51-Glu52 residues
near its N-terminus, which generates novel integrin binding sites
[8,27,28,29,30,31,32]. These post-translational modifications
change structure, affect biological properties, and may explain the
diversity of roles that sOPN plays in physiologic and pathologic
processes [27,32].
Recent evidence suggests that OPN may play a role in the
pathogenesis of asthma. Several investigators have shown that
OPN influences the pathophysiology of murine models of allergic
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airway disease. Osteopontin deficiency, generated by administra-
tion of blocking antibody or by genomic alteration (knockout
mice), is reported to protect against airway hyperresponsiveness
(AHR) and airway remodeling [33,34,35,36,37]. The state of
polymerization or fragmentation of OPN in these mice has not
been determined. In humans, polymorphism in the OPN gene
(SPP1) has been shown to be associated with asthma in a Puerto
Rican population [38]. Immunohistochemical analysis of endo-
bronchial biopsies has shown increased OPN expression in
bronchial epithelium and subepithelial inflammatory cells in
asthmatic subjects compared to non-asthmatic controls [33]. In
addition, four recent studies using ELISA assays revealed
increased levels of sOPN in BAL fluid and induced sputum in
asthmatic subjects [39,40,41,42]. However, the conformation of
sOPN in airways has not been characterized, nor has it been
shown whether there are differences in post-translational modifi-
cation of sOPN between healthy and asthmatic subjects,
particularly as TGM2, which polymerizes sOPN, is reported to
be more abundant in certain asthmatic subjects [43].
Given the above observations, we hypothesized (1) that sOPN
exists in different conformations including polymeric forms in
human airways, and (2) that the reported difference between
healthy and asthmatic subjects in expression of OPN is due to
higher abundance of polymeric sOPN in asthmatic airways. To
test these hypotheses, we characterized sOPN in human
respiratory tract lining fluid (RTLF, as represented by BAL and
induced sputum) from healthy and asthmatic subjects.
Methods
All work performed in this research was approved by the University
of California institutional review board, the Committee on Human
Research (CHR). Subjects were informed of the risks of the
experimental protocol and signed a CHR-approved consent form.
All subjects received financial compensation for their participation.
Study design
This study had a cross-sectional observational design and involved
two visits. During the first visit, subjects were consented and then
underwent history and physical examination, completion of a
medical questionnaire, spirometry, skin prick testing, and metha-
choline challenge testing. Subjects were then assigned to sputum
induction or bronchoscopy groups. During the second visit, subjects
underwent spirometry with and without bronchodilator, and sputum
induction or bronchoscopy according to their group assignment.
Human subjects
Please see Methods S1 for full details of human subject,
bronchoscopy, and sputum induction methods.
Subjects were recruited by public advertisements, and were
included in the study if they had a history of physician-diagnosed
asthma and AHR to inhaled methacholine (provocative concen-
tration of methacholine resulting in a 20% decrease in FEV1
compared with post-diluent [PC20] #8.0 mg/ml), verified in our
laboratory according to a standard protocol [44]. Healthy non-
asthmatic control subjects also were included in the study if they
had no history of asthma and had a negative methacholine
challenge test as defined by [PC20] .16.0 mg/ml.
Subjects were excluded if they had a history of cardiac or pulmonary
diseases other than asthma, oral corticosteroid use within the 3 months
prior to enrollment, or respiratory infection within 6 weeks prior to
enrollment. Subjects were excluded if they had more than 1 pack-year
lifetime history of prior tobacco use or had smoked within 6 months of
participating in the study, or if they had a history of intravenous or
inhaled illicit drug use. To avoid any possible corticosteroid effects,
subjects were requested to withhold inhaled corticosteroids for at least
2 weeks before each study session. Short-acting inhaled bronchodila-
tors were allowed throughout the course of the study.
In vitro polymerization of rOPN by transglutaminase 2
Human rOPN (1 mg/ml) (1433-OP/CF; R&D Systems; Min-
neapolis, MN) was incubated with recombinant human transglu-
taminase 2 (TGM2) (0.06 mg/ml) (4376-TG-050; R&D Systems)
in reaction buffer consisting of 5 mM CaCl2, 1 mM DTT, and
50 mM Tris-HCl (pH 7.5) at 37uC for 2 h (Figure 1B).
In vitro digestion of rOPN by thrombin
Human rOPN (1 mg/ml) or TGM2-treated (polymeric) rOPN
(1 mg/ml) was incubated with recombinant human thrombin
(0.02 mg/ml) (1473-SE; R&D Systems) in reaction buffer (0.1 M
ammonium bicarbonate) or in PBS at 37uC for 2 h (Figure 1B).
In vitro dephosphorylation and deglycosylation of rOPN
and sOPN
Samples were deglycosylated using a Protein Deglycosylation
Mix kit (P6039; New England Biolabs Inc., Ipswich, MA). Human
rOPN or human BAL (sOPN) was added to 10x glycoprotein
Denaturing Buffer, denatured by heating at 100uC for 10 min and
then incubated with 10x G7 Reaction Buffer and Deglycosylation
Enzyme Cocktail at 37uC for 4 h according to manufacturer
protocol (New England Biolabs). Human rOPN and BAL (sOPN)
were dephosphorylated with alkaline phosphatase (M0290S; New
England Biolabs) at 37uC for 2 h.
Western blot materials
Goat affinity-purified anti-human OPN polyclonal antibody
(AF1433) raised against natural human milk sOPN, anti-goat IgG-
HRP antibody (AB-108-C), and human rOPN (1433-OP) made in
a murine myeloma cell line were purchased from R&D Systems.
BSA, Tris-HCl, and Tween 20 were obtained from Sigma-Aldrich
(St. Louis, MO). Polymeric and thrombin-cleaved rOPN were
synthesized as described above.
Denaturing Western blot
Immunoblotting was performed using Invitrogen XCell Sure-
Lock Mini-Cell and XCell II BlotModule kit and reagents and
NuPAGE 4–12% gradient Bis-Tris gels (Life Technologies,
Carlsbad, CA). A total of 10 ml of each BAL or sputum fluid
samples was loaded on the gel. Protein concentrations were
measured separately and the optical densities were adjusted for
protein concentration as detailed below. Control recombinant
proteins (rOPN, polymeric and cleaved rOPN) as well as BAL and
sputum samples were reduced and denatured with 5 mM
dithiothreitol at 90uC for 10 min, electrophoresed by SDS-PAGE,
and transferred to polyvinylidene difluoride membranes (Invitro-
gen, Life Technologies, Carlsbad, CA) for immunodetection. The
membranes were blocked in 2% Tween in Tris-buffered saline
(TBS) containing BSA and probed using anti-human OPN
polyclonal antibodies overnight at 4uC and then detected using
appropriate horseradish peroxidase (HRP)-conjugated antibodies
and West-Dura chemiluminescent substrate. The chemilumines-
cent signal was visualized using Fluor Chem FC2 System (Cell
Biosciences, Santa Clara, CA).
Optical densitometry
Optical density was measured using ImageJ software (ver-
sion1.44, NIH, Bethesda, MD). Each sOPN band was measured
Osteopontin in Human Airways
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separately. The polymeric sOPN bands that produced a
continuous smear were measured as a single band. Other
polymeric bands were measured separately. For the purpose of
analysis, consistent with the described molecular weights of various
forms of sOPN and with our polymerization and cleavage
experiment, bands from 40 up to 90 kD were considered to be
monomeric. Bands $90 kD were considered as polymeric (bands
between 90 and 100 kD were considered dimeric sOPN) and
bands ,40 kD were considered to be cleaved.
For each subject, relative densitometry was determined
via measurement of the signal from each sOPN moiety relative
to the cumulative sOPN bands signal [for example, mono-
meric sOPN relative OD=ODmonomeric sOPN/(ODpolymeric sOPN+
ODmonomeric sOPN+ODcleaved sOPN].
Absolute densitometry for each band was determined as relative
signal intensity to the appropriate size rOPN control band signal [for
example, monomeric sOPN densitometry unit=ODmonomeric sOPN/
ODmonomeric rOPN 20 ng control and polymeric sOPN densitometry
Figure 1. Monomeric, cleaved, and polymeric rOPN, BAL, and sputum sOPN. 1A- Size exclusion chromatogram of rOPN and TGM2-treated
(polymerized) rOPN; V0: void volume; i: thyroglobulin (669 kD); ii: apoferritin (460 kD); iii: gamma globulin (158 kD); iv: bovine serum albumin
(65.5 kD); v: human chymase (30 kD). 1B- Immunoblot of rOPN, thrombin-cleaved rOPN, and TGM2-treated (polymerized) rOPN. Lane 1: rOPN; Lane 2:
rOPN treated with thrombin; Lane 3: polymeric rOPN made using TGM2. 1C- Immunoblot of BAL samples from 5 healthy and 5 asthmatic subjects
probed with affinity purified polyclonal anti-human sOPN antibody. 1D- Immunoblot of induced sputum samples from 5 healthy and 5 asthmatic
subjects probed with affinity purified polyclonal anti-human sOPN antibody.
doi:10.1371/journal.pone.0025678.g001
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unit =ODpolymeric sOPN/ODpolymeric rOPN 20 ng control]. The signal
intensity of polymeric sOPN was compared to the signal intensity of
smear band of 20 ng of synthesized polymeric rOPN.
Size exclusion (gel filtration) chromatography
Human rOPN samples [rOPN or TGM2-treated (polymeric)
rOPN] were injected onto a Superose 6 10/300 GL column (GE
Healthcare Life Sciences, Piscataway, NJ) equilibrated with
phosphate buffered saline (PBS, pH 7.4). The column was
calibrated on separate runs with thyroglobulin (669 kD), apofer-
ritin (460 kD), gamma globulin (158 kD), bovine serum albumin
(65.5 kD), and human chymase (30 kD).
Sample size and power calculations
Previous human studies reported detecting significant differenc-
es in ELISA-measured OPN concentrations with sample sizes of
17 to 35 subjects in each healthy or asthmatic group [39,40,41,45].
We based our sample size on the ability to detect a 10% difference
in optical density of sOPN moieties. A sample size of 35 for BAL
fluid samples provided statistical power of 81% with a two-sided
type I error of 5% to observe a minimal difference of 10% with the
assumption that the true difference between optical densities of
sOPN moieties is the same as its standard deviation; our sample of
33 subjects provided a power of 79%. For sputum samples, given
the reported larger variance in endpoints measured in sputum
versus BAL [46], we assumed the true difference between healthy
and asthmatic subjects to be 0.85 of its standard deviation. A
sample size of 50 thus provided statistical power of 83% with a
two-sided type I error of 5% to observe a minimal difference of
10%; our sample of 47 subjects provided a power of 81%.
Data management and analysis
All data were entered into a database developed in Microsoft
Excel 2000 (Microsoft, Redmond, WA). The absolute optical
densities from immunoblots were adjusted for protein concentra-
tion of corresponding BAL or sputum samples by division of the
signal by protein concentration or were adjusted in multivariate
regression models. The relative optical densities were not adjusted
as they were measured and calculated within the same sample
from the same subject.
Data were analyzed using STATA 10.0 software (STATA
Corp, College Station, TX). Student’s t-test (parametric data) and
Mann–Whitney U test (non-parametric data) were used for
comparisons between asthmatic and non-asthmatic subjects. P-
values less than 0.05 were considered to be statistically significant.
Results
Study subjects, BAL, and induced sputum
BAL fluid samples were obtained from 33 subjects (12 healthy
and 21 asthmatic subjects, Table S1). Induced sputum samples
were obtained from 47 subjects (27 healthy and 21 asthmatic
subjects, Table S2). All asthmatic subjects who were taking inhaled
corticosteroid discontinued their use 2 weeks prior to collection of
BAL or sputum. The concentrations of inflammatory cells in BAL
and sputum samples are shown in Tables S3 and S4. The
concentration of total protein in BAL samples was not significantly
different between healthy and asthmatic subjects.
Secreted OPN exists in polymeric, monomeric, and
cleaved forms in BAL and sputum
Immunoblotting of BAL samples with affinity-purified anti-
human OPN polyclonal antibody showed several different forms
of sOPN: a smeared band .250 kD along with a few other bands
in the 100 to 250 kD range representing polymeric (multimeric)
sOPN, a band at 90 kD likely representing dimeric sOPN, two
bands at 50 and 55 kD representing monomeric sOPN, and a
band at 25 kD representing cleaved sOPN (Figure 1C). The
molecular weights of these bands correlated with those of our
synthetic polymeric (TGM2-treated), monomeric, and thrombin-
cleaved rOPN bands (Figure 1B). The sputum samples showed a
similar pattern of bands as well as an additional band at 17 kD
likely representing an additional (non-thrombin) cleaved sOPN
(Figure 1D). To demonstrate polymerization of rOPN by TGM2
through an alternate technique, size fractionation of rOPN
(monomeric) or TGM2-treated rOPN (polymeric) was performed
using a Superose 6 gel filtration column equilibrated with PBS at
pH 7.4. Size fractionation showed that rOPN (monomeric rOPN
that migrated at a molecular weight of 55 kD on SDS-PAGE)
eluted at a single peak in the 200–240 kD range (Figure 1A),
suggesting that in phosphate buffered saline (PBS) and physiologic
pH, rOPN behaves as an oligomer (possibly tetramer). In contrast,
TGM2-treated rOPN (polymeric) eluted at two peaks: one in the
void volume (.5000 kD) and another identical to untreated rOPN
in the 200–240 kD range (Figure 1A), suggesting that the TGM2-
treated rOPN produced a highly polymerized large moiety that
eluted with the void volume.
Secreted OPN is highly glycosylated and phosphorylated
in BAL and sputum
Deglycosylation and dephosphorylation of rOPN decreased the
size of the rOPN band from 55 kD to 50 kD (Figure 2A).
Similarly, treatment of BAL samples showed the appearance of a
second band of sOPN at 50 kD (Figure 2B). In addition, the
deglycosylation and dephosphorylation caused an analogous shift
in the 90 kD band of sOPN down to about 80 kD. No significant
changes were observed in the polymeric sOPN band in BAL. The
sputum samples showed a similar pattern of shift in their bands
(Figure 2A).
Figure 2. Deglycosylation and dephosphorylation of rOPN and
BAL and sputum sOPN. Immunoblot of deglycosylation and
dephosphorylation of rOPN and sputum supernatant sOPN (2A) and
BAL fluid sOPN from representative subjects (2B) probed with
polyclonal anti-human sOPN antibody. DeGly: Deglycosylation Enzyme
Mix; Alk Phos: Alkaline Phosphatase.
doi:10.1371/journal.pone.0025678.g002
Osteopontin in Human Airways
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Most sOPN in BAL and sputum is in polymeric form
Relative densitometry of the individual BAL and sputum samples
from each subject showed that the intensity of the polymeric sOPN
bands was much higher relative to the intensity of the other forms
of sOPN, suggesting that most of sOPN in BAL and sputum is in
polymeric form (Figure 3). The polymeric sOPN OD accounted
for 86.9613.1% and 94.265.8% in BAL and sputum in all
subjects.
Asthmatic BAL and sputum samples have lower fraction
of polymeric and higher fraction of monomeric and
cleaved sOPN
Relative densitometry showed that compared to healthy
subjects, asthmatic subjects had a proportionately lower fraction
of polymeric sOPN and a higher fraction of monomeric sOPN in
BAL and sputum samples (Tables 1 and 2). In addition, asthmatic
subjects had a higher fraction of the 17 kD cleaved sOPN seen in
the sputum samples (Table 2). Similarly, in BAL samples, absolute
densitometry adjusted for protein concentration also showed that
the OD of polymeric sOPN was significantly higher and the OD of
monomeric sOPN was significantly lower in healthy subjects
compared to that of asthmatic subjects (Figure 4). In induced
sputum, absolute densitometry adjusted for protein concentration
showed a higher fraction of the 17 kD cleaved sOPN band in
asthmatic subjects (0.260.2 versus 0.160.1 densitometry unit/mg
protein in asthmatic versus healthy subjects, respectively, Mann-
Whitney p= 0.036), but no statistically significant difference was
detected in other bands.
Polymeric sOPN is associated with concentration of
alveolar macrophages in BAL in all subjects
The inflammatory cell counts in BAL samples of subjects are
shown in Table S2. In linear regression models, BAL polymeric
sOPN concentration (as measured by absolute optical density)
showed a significant association with increased cellularity in BAL
(correlation coefficient R= 0.66; p = 0.0002) and in particular
with alveolar macrophage concentration in BAL (Figure 5)
(correlation coefficient R= 0.61; p = 0.0007). These models
suggest that for every doubling concentration of polymeric sOPN
in BAL, the leukocyte count in BAL increased by a factor of
24.0% (95% CI: 12.0% to 37.3%), and alveolar macrophage
count in BAL increased by a factor of 22.1% (95% CI: 9.7% to
35.9%). Inclusion of age, sex, BMI, or BAL total protein
concentration did not significantly affect the model. There was no
association between inflammatory cells and monomeric or
cleaved sOPN in BAL samples. The concentration of sOPN in
sputum measured by densitometry did not correlate with sputum
cell count.
Figure 3. Secreted OPN in BAL and sputum. Relative optical density of polymeric, monomeric, and cleaved sOPN in BAL fluid and induced
sputum of healthy and asthmatic subjects. White: polymeric sOPN ($90 kD); light gray: monomeric sOPN (50–55 kD); dark gray: cleaved sOPN
(25 kD); black: cleaved sOPN (17 kD).
doi:10.1371/journal.pone.0025678.g003
Osteopontin in Human Airways
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Discussion
In this study, we found that (1) human RTLF contains sOPN in
polymeric, monomeric, and cleaved forms; (2) most of sOPN in
RTLF is in polymeric form; and (3) polymeric sOPN is associated
with higher cellular inflammation, and in particular higher
concentration of alveolar macrophages, in RTLF. Furthermore,
we found that monomeric rOPN behaves as a non-covalently-
bound oligomer under physiologic condition. While polymeric
sOPN has been identified in bone and calcified aorta [47,48] and
the presence of cleaved sOPN fragments has been detected in the
synovial fluid of patients with rheumatoid arthritis [49], our study
is the first to report the presence of polymeric and cleaved sOPN
in airways. In addition, we report that the sOPN in human RTLF
is highly glycosylated and phosphorylated. Finally, we found that,
contrary to our hypothesis, compared to healthy non-asthmatic
subjects, asthmatic subjects had a lower fraction of polymeric and
a higher fraction of monomeric and cleaved sOPN in RTLF.
Our finding that most of sOPN exists in polymeric form is
important since it has been demonstrated that post-translational
modifications of OPN (such as proteolytic cleavage, polymeriza-
tion, phosphorylation, and glycosylation) can significantly change
its structure and biological function. Studies have shown that
OPN is capable of polymerization either with itself or with other
extracellular matrix proteins such as fibronectin through the
catalytic action of tissue transglutaminase 2 (TGM2) [28,31]. The
elution pattern on size fractionation along with SDS-PAGE gel
migration behavior of polymeric rOPN in our study suggests that
polymeric sOPN in human airways also forms a large covalently-
bound structure with molecular weight .5000 kD. While the
functional relevance of this enormous molecule may be evident in
bone tissue, its functional role in human airways is unclear and
Table 1. Relative optical density (OD) for sOPN bands and OD-based concentration of sOPN in BAL.
BAL sOPN (mg/ml) Relative OD Relative OD Relative OD p-value
All subjects
(N=33)
All subjects
(N=33)
Non-asthmatic
Subjects (N=12)
Asthmatic
Subjects (N=21)
Polymeric sOPN
(90 & .100 kD)
1.3261.29 86.9613.1 94.169.0 83.8613.5 0.019
0.99 [0.62, 1.57] 90.1 [77.9, 100.0] 100.0 [85.3, 100.0] 81.1 [76.2, 95.7]
Polymeric sOPN
(.100 kD)
0.7861.16 39.1627.0 53.7625.2 32.8625.7 0.048
0.45 [0.07, 0.73] 34.6 [13.6, 61.4] 61.4 [35.6, 68.7] 28.4 [8.7, 51.0]
Dimeric sOPN (90 kD) 0.5560.32 47.9625.1 40.3623.7 51.1625.6 0.248
0.47 [0.25, 0.75] 44.8 [29.9, 66.7] 38.6 [22.0, 49.7] 47.6 [31.5, 67.2]
Monomeric sOPN
(50–55 kD)
0.1560.19 9.9610.3 3.265.3 12.8610.7 0.008
0.11 [0.00, 0.21] 6.6 [0.0, 17.0] 0.0 [0.0, 5.7] 15.0 [4.3, 18.2]
Cleaved sOPN (25 kD) 0.0660.16 3.264.3 2.765.5 3.360.8 0.199
0.02 [0.00, 0.05] 1.1 [0.0, 4.6] 0.0 [0.0, 0.0] 3.1 [0.0, 4.6]
Values are expressed as mean6 SD and median [interquartile range]. Total concentration of sOPN were 1.5461.43 (1.17 [0.80, 1.78] in BAL. P-values are for comparisons
(Mann-Whitney test) of relative OD of various bands between healthy and asthmatic subjects. Significant p-values are shown in bold.
doi:10.1371/journal.pone.0025678.t001
Table 2. Relative optical density (OD) for sOPN bands and OD-based concentration of sOPN in sputum.
Sputum sOPN (mg/ml) Relative OD Relative OD Relative OD p-value
All subjects
(N=33)
All subjects
(N=47)
Non-asthmatic
Subjects (N=27)
Asthmatic
Subjects (N=20)
Polymeric sOPN
($90 kD) (%)
2.4562.97 94.265.8 96.463.2 91.661.6 0.009
1.59 [0.58, 2.67] 94.6 [92.7, 98.7] 96.5 [94.6, 99.4] 94.0 [89.0, 97.5]
Monomeric sOPN
(50–55 kD) (%)
0.2860.47 3.263.3 2.061.8 4.564.1 0.025
0.08 [0.00, 0.37] 2.6 [0.7, 4.4] 1.9 [0.0, 2.9] 3.8 [1.6, 6.2]
Cleaved sOPN (25 kD) (%) 0.1060.15 1.061.3 0.761.1 1.461.5 0.064
0.08 [0.00, 0.08] 0.5 [0.0, 1.5] 0.3 [0.0, 0.9] 1.2 [0.3, 1.6]
Cleaved sOPN (17 kD) (%) 0.1160.17 1.761.9 0.961.4 2.662.0 0.005
0.03 [0.01, 0.13] 0.9 [0.3, 2.7] 0.6 [0.0, 1.0] 2.7 [0.6, 4.1]
Values are expressed as mean 6 SD and median [interquartile range]. Total concentration of sOPN was 3.0363.41(2.25 [0.80, 3.08]) mg/ml in sputum samples. P-values
are for comparisons (Mann-Whitney test) of relative OD of various bands between healthy and asthmatic subjects. Significant p-values are shown in bold.
doi:10.1371/journal.pone.0025678.t002
Osteopontin in Human Airways
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demands further investigation. Polymeric OPN has been reported
to increase its binding to collagen, and enhance its biologic activity
including increased integrin binding, which results in enhanced
cell adhesion, spreading, migration, and focal contact formation
[27,50,51]. Recent in vitro and animal studies have shown that
polymerization of OPN causes a gain of chemotactic activity for
neutrophils through its interaction with a9b1 integrin [27,32].
However, further studies are needed to determine polymeric
sOPN function in human airways. In addition, our finding that the
rOPN behaves as a non-covalently-bound oligomer in vitro under
physiologic condition is interesting and needs further investigation
to determine whether sOPN in vivo also behaves as an oligomer.
Previous studies also have shown that OPN has a conserved
thrombin cleavage site. Thrombin cleavage exposes a new
carboxyl-terminus (SVVYGLR) in the cleaved OPN (known
as OPN-R) that interacts with several other integrins in a
non-RGD-dependent manner [52,53,54,55,56]. The role of
SVVYGLR in thrombin-cleaved OPN has been recently
demonstrated by reports that in a murine model of rheumatoid
arthritis a monoclonal antibody directed against this site inhibits
proliferation of synovium, infiltration of inflammatory cells, and
development of bone erosions. [57] In addition to thrombin,
other proteases such as plasmin and cathepsin D were reported to
be able to cleave OPN to produce fragments of smaller size (14 to
Figure 5. Alveolar macrophages and sOPN. Correlation between alveolar macrophage concentration (log base 2) and polymeric sOPN optical
density (log base 2) in BAL (R = 0.61; p = 0.0007).
doi:10.1371/journal.pone.0025678.g005
Figure 4. Densitometry of sOPN in BAL. Absolute optical density adjusted for protein content of polymeric, monomeric, and cleaved sOPN in
BAL fluid of healthy and asthmatic subjects.
doi:10.1371/journal.pone.0025678.g004
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19 kD) by plasmin and cathepsin-D [58]. In our study, we found
that a significant portion of non-polymeric sOPN in sputum is in
a cleaved form (17 kD) smaller than the thrombin-cleaved rOPN.
The presence of this band, which was absent in BAL samples,
may be explained by alternate phosphorylation/glycosylation
sites, cleavage by alternate protease(s) such as plasmin or
cathepsin D, and/or alternate sources of sOPN production
within the upper airways or saliva that are absent in lower
airways. Further studies are needed to determine the structure of
the observed RTLF sOPN fragments, proteases involved in their
formation, and their functional consequence.
Furthermore, we found a significant association between
polymeric sOPN and concentration of alveolar macrophages in
BAL. These findings suggests a chemotactic and/or anti-apoptotic
role of polymeric sOPN for alveolar macrophages in airways, and
are consistent with other studies showing that OPN acts as a direct
chemoattractant and as a survival factor for inflammatory cells
such as macrophages [25,27,59,60,61,62,63,64,65]. While poly-
meric OPN was reported to have enhanced neutrophil chemo-
tactic ability compared to monomeric OPN [27,32], we did not
observe a relationship between polymeric sOPN and concentra-
tion of neutrophils in BAL. However, in the absence of a stimulus
for neutrophilia such as airway injury, the concentration of
neutrophils in BAL is very low (about 3% of total leukocyte
count), and thus the presence of an association may be difficult to
show with such low fractions of neutrophils. Further studies of
polymeric sOPN in models of airway injury such as oxidative
injury, smoke injury, infection, or acute respiratory distress
syndrome (ARDS) may help to investigate its role in recruitment
and survival of airway neutrophils and other inflammatory or
airway cells.
Previous studies showed a higher level of sOPN in asthma. Our
study adds to these studies by showing that in asthma, the RTLF
contains lower fraction of polymeric and higher fraction of
monomeric and cleaved sOPN. Potential explanations for these
differences are higher proteolytic cleavage and/or lower polymer-
ization in airways of subjects with asthma. Polymerization of OPN
is thought to be performed by TGM2, which a recent report has
suggested to be increased in asthma [66]. As such, inhibition of
TGM2 activity or higher proteolytic cleavage may be the more
likely explanations for the presence of lower polymeric sOPN
that we observed in asthma. Cleaved sOPN has been suggested
to interact with CD44 [67,68] and may play a role in the
pathogenesis of asthma through this mechanism [69].
There are a few potential limitations to our study. First, we
loaded equal volumes of BAL, and not equal amounts of total
protein on our immunoblots. Our rationale is that all BAL
procedures were performed by instilling the same amount (100 ml)
of saline in subjects’ right middle lobe, which should result in
similar dilution of all subjects’ RTLF. Loading different BAL
volumes with the same amount of total protein could potentially
obscure any real differences as the amount of total protein in
airways is a function of airway biology and disease. In our analysis,
we analyzed relative densitometry for BAL of each subject, which
should bypass the potential confounding of equal volumes vs.
equal protein amounts. In addition, we adjusted the measured
absolute densitometries for total protein concentration by dividing
the absolute densities by total protein concentration of each
sample, and in our regression models, we included the total
protein concentrations as a possible predictor. Second, sputum
samples may be contaminated with saliva and may not exclusively
represent the RTLF of lower airways. While our sputum induction
method is different than the method that isolates and homogenizes
mucus plugs as a representation of RTLF, it is the method adopted
and in current use by the NIH Asthma and COPD Clinical
Networks, and has been shown to be a valid method of RTLF
assessment. In this method, saliva is cleared from the mouth before
each expectoration of sputum and so there is minimal contam-
ination by saliva. Furthermore, the quality of samples is assessed
by measurement of squamous cells and those with high con-
tamination with squamous cells are routinely excluded. The close
correlation between BAL samples and induced sputum samples
obtained by our induction method is reassuring in that this method
likely provides a reasonable sample of RTLF. Third, our study is
an observational study, and does not provide data on functional
sequelae of polymerization or fragmentation of sOPN. While, a
few studies have shown important functional consequences for
polymerization of OPN [27,32], further studies are needed to
better understand the role of sOPN in lung pathophysiology.
However, our study provides important information that will be
useful in appropriate design of such studies particularly as it
implies that any administered OPN may become polymerized in
vitro or in vivo through the action of TGM2.
Conclusions
In conclusion, our results suggest (1) that sOPN in human
airways undergoes extensive post-translational modification by
polymerization and proteolytic fragmentation, (2) that sOPN is
more fragmented and less polymerized in subjects with mild to
moderate asthma, and (3) that sOPN may contribute to
recruitment or survival of alveolar macrophages.
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